Compare Johnson & Johnson (JNJ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Novavax Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Johnson & Johnson is far larger — about 339.6× Novavax Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Novavax Inc for 59 Days on average.
| JNJ | NVAX | |
|---|---|---|
Market Cap | $618.09B | $1.82B |
Volume | 6,050,983 | 6,198,505 |
Sector | Health | Health |
52-Week High | $278.43 | $12.75 |
52-Week Low | $186.00 | $6.22 |
Typical Hold Time | 129 Days | 59 Days |
Enterprise Value | $646.37B | $1.39B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
